Exhibit 99.1
VIA SEDAR
October 1, 2020
Autorité des marchés financiers
Alberta Securities Commission
British Columbia Securities Commission
Manitoba Securities Commission
Ontario Securities Commission
| Subject: | Acasti Pharma Inc. (the “Corporation”) | |
| Report on the Voting Results, in accordance with article 11.3 of Regulation 51-102 respecting Continuous Disclosure Obligations (“Regulation 51-102”) |
Following the annual and special meeting of shareholders of the Corporation held on September 30, 2020 (the “AGM”), this report presents the items voted on during the AGM and the corresponding voting results, in accordance with article 11.3 of Regulation 51-102. For more detailed information on the proposals submitted to shareholders, please refer to the management information circular and proxy statement of the Corporation dated August 31, 2020 (the “Circular”).
According to the scrutineer’s reports, being present in person or by proxy, were the holders of 10,279,286 common shares, or 10.61%, of the 96,869,143 common shares issued and outstanding on September 8, 2020, the record date for the AGM.
The following individuals were elected as directors of Acasti at its AGM: Roderick N. Carter, Jean-Marie (John) Canan, Jan D’Alvise and Donald Olds.
1. Election of the directors of the Corporation for the ensuing year
| Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
| Roderick N. Carter | 7,689,988 | 74.81% | 2,589,298 | 25.19% |
| Jean-Marie (John) Canan | 7,736,464 | 75.26% | 2,542,822 | 24.74% |
| Jan D’Alvise | 7,681,263 | 74.73% | 2,598,023 | 25.27% |
| Donald Olds | 7,784,581 | 75.73% | 2,494,705 | 24.27% |
2. Appointment of KPMG LLP as auditors for the ensuing year and to authorize the board of directors of the Corporation (the “Board”) to fix their remuneration
| Votes Cast For | % Votes Cast For | Votes Cast Against | % Cast Votes Against |
| 8,187,946 | 90.54% | 855,557 | 9.46.% |
3. Ordinary resolution approving an advisory (non-binding) resolution approving the compensation of our named executive officers, as more particularly described in the Circular
| Votes Cast For | % Votes Cast For | Votes Cast Against | % Votes Cast Against |
| 5,222,830 | 58.62% | 3,687,193 | 41.38% |
4. Ordinary resolution approving an advisory (non-binding) resolution on the frequency of the future “say on pay” votes, as more particularly described in the Circular
| Number of Shares | Percentage of Votes Cast | ||||
| 1 Year | 2 Year | 3 Year | 1 Year | 2 Year | 3 Year |
| 7,035,191 | 320,698 | 2,175,841 | 73.81% | 3.36% | 22.83% |
5. Ordinary resolution approving, ratifying and confirming certain amendments to the Corporation’s stock option plan, as more particularly described in the Circular
| Votes Cast For | % Votes Cast For | Votes Cast Against | % Votes Cast Against |
| 4,786,055 | 54.52% | 3,993,282 | 45.48% |
(Disinterested Shareholders only – 159,500 shares are excluded)
6. Ordinary resolution approving, ratifying and confirming certain amendments to the Corporation’s equity incentive plan, as more particularly described in the Circular
| Votes Cast For | % Votes Cast For | Votes Cast Against | % Votes Cast Against |
| 4,881,604 | 55.56% | 3,904,357 | 44.44% |
(Disinterested Shareholders only – 159,500 shares are excluded)
7. Ordinary resolution approving, ratifying and confirming the adoption of the amended and restated general by-law of the Corporation, as more particularly described in the Circular
| Votes Cast For | % Votes Cast For | Votes Cast Against | % Votes Cast Against |
| 6,083,640 | 72.98% | 2,252,032 | 27.02% |
Sincerely,
/s/ Jan D’Alvise
Jan D’Alvise
Chief Executive Officer